MX394082B - Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim. - Google Patents

Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.

Info

Publication number
MX394082B
MX394082B MX2020011085A MX2020011085A MX394082B MX 394082 B MX394082 B MX 394082B MX 2020011085 A MX2020011085 A MX 2020011085A MX 2020011085 A MX2020011085 A MX 2020011085A MX 394082 B MX394082 B MX 394082B
Authority
MX
Mexico
Prior art keywords
thiazolecarboxamide
kinase inhibitors
compounds useful
pim kinase
bond
Prior art date
Application number
MX2020011085A
Other languages
English (en)
Spanish (es)
Other versions
MX2020011085A (es
Inventor
Anlai Wang
Chu-Biao Xue
Fenglei Zhang
Hao Feng
Jincong Zhuo
Jun Pan
Ke Zhang
Wenqing Yao
Yun-Long Li
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of MX2020011085A publication Critical patent/MX2020011085A/es
Publication of MX394082B publication Critical patent/MX394082B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020011085A 2013-01-15 2014-01-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim. MX394082B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361752897P 2013-01-15 2013-01-15
US201361790952P 2013-03-15 2013-03-15
US201361859118P 2013-07-26 2013-07-26
PCT/US2014/011486 WO2014113388A1 (en) 2013-01-15 2014-01-14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2020011085A MX2020011085A (es) 2022-07-20
MX394082B true MX394082B (es) 2025-03-24

Family

ID=50031607

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011085A MX394082B (es) 2013-01-15 2014-01-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
MX2015009057A MX376306B (es) 2013-01-15 2014-01-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015009057A MX376306B (es) 2013-01-15 2014-01-14 Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.

Country Status (35)

Country Link
US (7) US9200004B2 (enExample)
EP (3) EP2945939B1 (enExample)
JP (3) JP6554037B2 (enExample)
KR (2) KR102403306B1 (enExample)
CN (2) CN105051029B (enExample)
AR (1) AR094664A1 (enExample)
AU (3) AU2014207691B2 (enExample)
BR (2) BR112015016793B1 (enExample)
CA (1) CA2897333C (enExample)
CL (1) CL2015001985A1 (enExample)
CR (1) CR20150412A (enExample)
CY (1) CY1122933T1 (enExample)
DK (1) DK2945939T3 (enExample)
EA (1) EA035929B1 (enExample)
EC (1) ECSP15035343A (enExample)
ES (2) ES2941292T3 (enExample)
HR (1) HRP20200770T1 (enExample)
HU (1) HUE050215T2 (enExample)
IL (1) IL239886B (enExample)
LT (1) LT2945939T (enExample)
ME (1) ME03780B (enExample)
MX (2) MX394082B (enExample)
NZ (2) NZ710079A (enExample)
PE (2) PE20151448A1 (enExample)
PH (2) PH12015501567B1 (enExample)
PL (1) PL2945939T3 (enExample)
PT (1) PT2945939T (enExample)
RS (1) RS60244B1 (enExample)
SG (3) SG11201505347VA (enExample)
SI (1) SI2945939T1 (enExample)
SM (1) SMT202000244T1 (enExample)
TW (2) TW201932456A (enExample)
UA (1) UA121098C2 (enExample)
WO (1) WO2014113388A1 (enExample)
ZA (1) ZA202108141B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10722505B2 (en) * 2014-10-31 2020-07-28 Genoscience Pharma Substituted 2,4 diamino-quinoline as new anticancer agents
CN104876929B (zh) * 2015-05-15 2016-10-05 华南理工大学 一种1,2,3,4-四氢萘啶类化合物的合成方法及应用
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) * 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106336371A (zh) * 2016-08-16 2017-01-18 成都百事兴科技实业有限公司 叔丁氧羰基‑l‑焦谷氨酸甲酯的合成方法
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP2022506973A (ja) * 2018-11-09 2022-01-17 プレリュード セラピューティクス，インコーポレイティド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020221334A1 (en) * 2019-04-30 2020-11-05 City University Of Hong Kong Pim1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
AU2023372386A1 (en) 2022-10-31 2025-05-08 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms
WO2025117722A1 (en) * 2023-11-27 2025-06-05 Rubedo Life Sciences, Inc. Carbon linked bcl inhibitors and senolytic compounds and uses thereof

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
AU2002246864A1 (en) 2000-12-27 2002-07-24 The Trustees Of Columbia University In The City Of New York Pim kinase-related methods
DE10123055A1 (de) 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase
DE10226702A1 (de) 2002-06-14 2004-09-09 Grünenthal GmbH Antisense Oligonukleotide gegen PIM1
US20040142864A1 (en) 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
WO2006078228A1 (en) 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005033310A1 (de) 2003-10-01 2005-04-14 Grünenthal GmbH Pim-1-spezifische dsrna-verbindungen
WO2006006569A1 (ja) 2004-07-12 2006-01-19 Nihon Nohyaku Co., Ltd. フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法
AU2005321966B2 (en) 2004-12-28 2011-11-17 Atnx Spv, Llc Compositions and methods of treating cell proliferation disorders
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
AU2006302174B2 (en) 2005-10-06 2013-06-20 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
ATE533770T1 (de) 2005-10-06 2011-12-15 Schering Corp Pyrazolopyrimidine als proteinkinaseinhibitoren
EP1948663B1 (en) 2005-10-21 2011-09-14 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
US8318723B2 (en) 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
AU2007314305B2 (en) * 2006-10-31 2013-01-24 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
CA2682231A1 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
CA2685106A1 (en) 2007-04-25 2008-11-06 Exelixis, Inc. 6-phenylpyrimidinones as pim modulators
US8324231B2 (en) 2007-04-25 2012-12-04 Exelixis, Inc. Pyrimidinones as casein kinase II (CK2) modulators
CN101801958B (zh) 2007-07-19 2014-01-29 默沙东公司 作为蛋白质激酶抑制剂的杂环酰胺化合物
KR20100042287A (ko) * 2007-07-31 2010-04-23 쉐링 코포레이션 항암요법으로서의 항-유사분열제 및 아우로라 키나제 억제제 조합물
AR067813A1 (es) 2007-08-06 2009-10-21 Janssen Pharmaceutica Nv Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
WO2009064486A2 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
JP2011503207A (ja) 2007-11-16 2011-01-27 サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
CN102036561A (zh) 2008-02-29 2011-04-27 赛林药物股份有限公司 蛋白激酶调节剂
AR070531A1 (es) * 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) * 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
US20110294789A1 (en) 2008-05-12 2011-12-01 Amnestix, Inc. Compounds for rho kinase inhibition and for improving learning and memory
AU2009267048A1 (en) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8759338B2 (en) 2008-09-02 2014-06-24 Novartis Ag Heterocyclic kinase inhibitors
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
MX2011002367A (es) 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CN102459270B (zh) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
US20120128631A1 (en) 2009-05-19 2012-05-24 San Diego State University (SDSU) Foundation, dba San Diego State University (SDSU) Research Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
WO2010135571A1 (en) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
NZ596571A (en) 2009-05-20 2013-03-28 Cylene Pharmaceuticals Inc Pyrazolopyrimidines and related heterocycles as kinase inhibitors
TW201100429A (en) * 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
IN2012DN02596A (enExample) 2009-08-26 2015-08-28 Cylene Pharmaceuticals Inc
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN102625803A (zh) 2009-09-11 2012-08-01 赛林药物股份有限公司 药学上有用的杂环-取代的内酰胺
BR112012005970A2 (pt) 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
AU2010295622A1 (en) 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
US8404677B2 (en) 2009-10-29 2013-03-26 Genosco Kinase inhibitors
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
CN102712601A (zh) 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
US8853235B2 (en) 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075613A1 (en) 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
CN102884062B (zh) 2009-12-23 2016-08-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2794801C (en) 2010-04-07 2019-01-15 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012004217A1 (en) 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
US8227773B2 (en) 2010-07-29 2012-07-24 Axcelis Technologies, Inc. Versatile beam glitch detection system
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
CA2812223C (en) 2010-12-17 2019-03-12 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012101029A1 (en) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
EP2668190B1 (en) 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
JP6039585B2 (ja) 2011-02-25 2016-12-07 アレイ バイオファーマ、インコーポレイテッド Ｐｉｍキナーゼ阻害剤としてのトリアゾロピリジン化合物
EP2681197A1 (en) 2011-03-04 2014-01-08 Novartis AG Tetrasubstituted cyclohexyl compounds as kinase inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2012245344B2 (en) 2011-04-22 2017-11-09 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
CA2834166A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
CN103687858B (zh) 2011-05-17 2017-11-21 拜耳知识产权有限责任公司 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
CA2872979C (en) 2011-05-19 2020-02-18 Joaquin Pastor Fernandez Macrocyclic compounds as protein kinase inhibitors
KR20140048891A (ko) 2011-05-27 2014-04-24 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 2-벤질리덴-2H-벤조[b][1,4]티아진-3(4H)-온, 이의 유도체, 및 이의 치료적 용도
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
HK1197063A1 (en) 2011-06-22 2015-01-02 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
CN102924446B (zh) 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
CN103874700B (zh) 2011-08-12 2018-03-30 霍夫曼-拉罗奇有限公司 吡唑并[3,4‑c]吡啶化合物和使用方法
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
JP5843524B2 (ja) 2011-09-02 2016-01-13 キヤノン株式会社 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103814029B (zh) 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
KR20140074964A (ko) 2011-09-27 2014-06-18 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EP2788350B1 (en) 2011-10-07 2017-12-06 Nerviano Medical Sciences S.r.l. 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
ES2639064T3 (es) 2011-10-07 2017-10-25 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
CN104011046B (zh) 2011-11-04 2017-05-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
WO2013134079A1 (en) 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104321326B (zh) 2012-04-04 2017-05-31 拜耳医药股份有限公司 氨基取代的咪唑并哒嗪
TWI572605B (zh) 2012-04-26 2017-03-01 必治妥美雅史谷比公司 血小板聚集之抑制劑
JP6042529B2 (ja) 2012-04-27 2016-12-14 ノバルティス アーゲー 環式橋頭エーテルｄｇａｔ１阻害剤
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
CN104302638B (zh) 2012-05-15 2016-08-24 诺华股份有限公司 用于抑制abl1、abl2和bcr-abl1的活性的苯甲酰胺衍生物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2013175388A1 (en) 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN104428299B (zh) 2012-06-27 2018-05-11 霍夫曼-拉罗奇有限公司 5-氮杂吲唑化合物及其使用方法
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
SI2900657T1 (sl) 2012-09-26 2020-07-31 F. Hoffmann-La Roche Ag Ciklični eter pirazol-4-il-heterociklil-karboksamidne spojine in načini uporabe
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP2920176B1 (en) 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines as mknk1 kinase inhibitors
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
PT4190786T (pt) 2012-12-07 2025-05-29 Vertex Pharma Compostos úteis como inibidores da quinase atr
KR102075885B1 (ko) 2012-12-18 2020-02-11 버텍스 파마슈티칼스 인코포레이티드 세균 감염 치료용 만노스 유도체
CN104968656B (zh) 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
FR3000569B1 (fr) 2013-01-03 2015-02-13 Peugeot Citroen Automobiles Sa Dispositif d'eclairage a ecran a bord(s) lumineux
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TWI657090B (zh) 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US20160052926A1 (en) 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
UY35421A (es) 2013-03-15 2014-10-31 Nihon Nohyaku Co Ltd Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
PE20151900A1 (es) 2013-03-15 2016-01-20 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
EA029309B1 (ru) 2013-03-15 2018-03-30 Идорсиа Фармасьютиклз Лтд Производные пиридин-4-ила в качестве агонистов s1p/edg1
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
CN109134440A (zh) 2013-03-15 2019-01-04 美国陶氏益农公司 除草化合物及其作为除草剂的用途
CN105051015B (zh) 2013-03-15 2018-09-25 日本烟草产业株式会社 吡唑-酰胺化合物和其医药用途
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors

Also Published As

Publication number Publication date
CL2015001985A1 (es) 2015-10-02
JP2020200338A (ja) 2020-12-17
EP4186897A1 (en) 2023-05-31
JP6987937B2 (ja) 2022-01-05
KR102311840B1 (ko) 2021-10-14
RS60244B1 (sr) 2020-06-30
HRP20200770T1 (hr) 2020-07-24
KR20210110754A (ko) 2021-09-08
CA2897333A1 (en) 2014-07-24
TW201444823A (zh) 2014-12-01
EP3670506B1 (en) 2023-01-04
ZA202108141B (en) 2023-06-28
US11229631B2 (en) 2022-01-25
ES2941292T3 (es) 2023-05-19
LT2945939T (lt) 2020-07-27
EP2945939A1 (en) 2015-11-25
US10265307B2 (en) 2019-04-23
US9200004B2 (en) 2015-12-01
NZ710079A (en) 2020-01-31
JP2016505020A (ja) 2016-02-18
MX2015009057A (es) 2015-10-05
EP3670506A1 (en) 2020-06-24
MX2020011085A (es) 2022-07-20
KR102403306B1 (ko) 2022-06-02
SI2945939T1 (sl) 2020-08-31
BR122019024759B1 (pt) 2022-02-08
US20190209537A1 (en) 2019-07-11
JP2019206539A (ja) 2019-12-05
CN105051029A (zh) 2015-11-11
SG10201705662WA (en) 2017-08-30
TWI662030B (zh) 2019-06-11
EP2945939B1 (en) 2020-03-04
BR112015016793A2 (pt) 2017-07-11
JP6775645B2 (ja) 2020-10-28
WO2014113388A1 (en) 2014-07-24
US20200405702A1 (en) 2020-12-31
ME03780B (me) 2021-04-20
US10517858B2 (en) 2019-12-31
PE20191245A1 (es) 2019-09-18
IL239886A0 (en) 2015-08-31
TW201932456A (zh) 2019-08-16
BR112015016793B1 (pt) 2021-12-28
ECSP15035343A (es) 2017-03-31
CY1122933T1 (el) 2021-10-29
NZ749911A (en) 2020-02-28
UA121098C2 (uk) 2020-04-10
EA201591339A1 (ru) 2015-12-30
US9849120B2 (en) 2017-12-26
AU2020201114B2 (en) 2021-03-25
KR20150113019A (ko) 2015-10-07
AU2020201114A1 (en) 2020-03-05
AU2018217210C1 (en) 2020-08-27
US20140200227A1 (en) 2014-07-17
CR20150412A (es) 2015-10-27
AR094664A1 (es) 2015-08-19
ES2790419T3 (es) 2020-10-27
AU2014207691A1 (en) 2015-08-06
HUE050215T2 (hu) 2020-11-30
US10828290B2 (en) 2020-11-10
JP6554037B2 (ja) 2019-07-31
PE20151448A1 (es) 2015-09-28
SG11201505347VA (en) 2015-08-28
CA2897333C (en) 2021-07-06
MX376306B (es) 2025-03-07
US20170182017A1 (en) 2017-06-29
PL2945939T3 (pl) 2020-08-24
DK2945939T3 (da) 2020-03-23
US20150329534A1 (en) 2015-11-19
US20200155527A1 (en) 2020-05-21
CN105051029B (zh) 2018-07-31
PH12015501567A1 (en) 2015-09-21
US9550765B2 (en) 2017-01-24
PH12020500485A1 (en) 2021-06-14
CN108715590A (zh) 2018-10-30
EA035929B1 (ru) 2020-09-02
AU2018217210B2 (en) 2020-02-20
SMT202000244T1 (it) 2020-07-08
IL239886B (en) 2021-03-25
CN108715590B (zh) 2022-03-08
AU2014207691B2 (en) 2018-08-30
HK1216424A1 (en) 2016-11-11
US20180193323A1 (en) 2018-07-12
SG10201912524QA (en) 2020-04-29
AU2018217210A1 (en) 2018-08-30
PH12015501567B1 (en) 2015-09-21
PT2945939T (pt) 2020-06-08

Similar Documents

Publication Publication Date Title
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
NZ736709A (en) Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
MD4666B1 (ro) Inhibitori ai Syk
EA201791576A1 (ru) Ингибитор jak
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
JO3603B1 (ar) مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201790660A1 (ru) Ингибитор киназ
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
EA201692300A1 (ru) Производные карбоксамида
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
EA201491878A1 (ru) Замещенные ксантиновые производные
EA202090672A2 (ru) ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors